BTLA, B and T lymphocyte associated, 151888

N. diseases: 74; N. variants: 6
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 GeneticVariation group BEFREE More studies should be conducted to evaluate whether BTLA polymorphisms may influence the susceptibility of cancer in the future. 31774112 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 Biomarker group BEFREE The BTLA-HVEM checkpoint axis plays extensive roles in immunomodulation and diseases, including cancer and autoimmune disorders. 31562209 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 Biomarker group BEFREE BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19<sup>high</sup> B lymphocytes. 31753019 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE <b>Results:</b> We found increased an expression of PD-1 and Tim-3 but a decreased expression of BTLA on TILs when compared with peripheral blood from multiple types of cancer. 31709176 2019
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE Using mutants of BTLA signaling motifs, we uncovered a costimulatory function mediated by Grb2 through enhancing the secretion of IL-2 and the activation of Src after TCR stimulation.<b>Conclusions:</b> Our data portrays BTLA as a molecule with the singular ability to provide both costimulatory and coinhibitory signals to activated CD8<sup>+</sup> T cells, resulting in extended survival, improved tumor control, and the development of a functional recall response.<i>Clin Cancer Res; 23(20); 6151-64.©2017 AACR</i>. 28754817 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 GeneticVariation group BEFREE Despite the important role of BTLA in maintaining immune homeostasis, relatively little studies were devoted to the relationship of polymorphisms in the gene encoding BTLA with susceptibility to autoimmune disease and cancer. 25182981 2015
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.070 AlteredExpression group BEFREE Here we summarize the recent advances made on PD1/PD1 ligands expression in cancer and we discuss about another couple of inhibitory molecules, BTLA and its ligand HVEM and their potential role in immune escape. 23439006 2013